We sat down with Haran Maheson, Vice President & Head of Oncology at Daiichi Sankyo UK, to find out more about the company’s rapid growth, their vision to transform cancer care in the UK ...

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug ... 5% on Tuesday after results from the company's lung cancer trials showed that its ...

Daiichi Sankyo Company, Limited, a leading Japanese pharma, excels in ADC technology, with flagship product Enhertu driving significant revenue growth and global market leadership. Strong ...

Jefferies analyst Stephen Barker maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) today and set a price target of ...

Daiichi Sankyo has announced that Hiroyuki Okuzawa will succeed Sunao Manabe as its CEO from 1 April 2025. The company's board of directors followed the nomination committee's report, appointing ...

Daiichi Sankyo (DSNKY) and AstraZeneca’s (AZN) Enhertu has been approved in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone ...